Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NabucCO)
Metastatic Pancreatic Cancer
About this trial
This is an interventional treatment trial for Metastatic Pancreatic Cancer focused on measuring mPC
Eligibility Criteria
Inclusion Criteria:
- . Males or females ≥ 18 years old and ≤ 75 years old;
- Histological or cytological evidence of a diagnosis of pancreatic ductal adenocarcinoma;
- Written informed consent prior to any study-specific procedures; 4. Measurable metastatic disease, defined in according to RECIST Version 1.1 (Eisenhower et al. 2009), that had not previously been treated with CT for metastatic disease;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 ;
- Absence of previous abdominal radiotherapy on target lesions (except radiation therapy analgesic if it has not been performed on measurable targets);
- Absence of heart failure or angina or infarction within 12 months previous inclusion;
- Have adequate organ function including:
Hematologic: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L.
Hepatic: Bilirubin ≤ 1.5 times upper limits of normal (ULN) (Pts may have endoscopic or radiologic stenting to treat biliary obstructions).
Renal: Serum creatinine within normal limits ≤1.5 times ULN.
Exclusion Criteria:
- Age of 76 years or older;
- Endocrine or acinar pancreatic carcinoma;
- Previous radiotherapy for measurable lesions;
- Central nervous system metastasis;
- Other concomitant cancer or history of cancer outside a carcinoma in situ of the cervix or basal or squamous cell of the skin;
- Pts already included in another clinical trial with other experimental drugs;
- Current active infection;
- Have serious pre-existing medical conditions or serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris, or a clinically significant history of cardiac disease or uncontrolled diabetes mellitus);
- Females who are pregnant or lactating;
- Unable to undergo medical test for geographical, social or psychological reason
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
Sites / Locations
- Ospedale Sacro cuore di Gesù - FATEBENEFRATELLI
- IRCCS Ospedale Casa Sollievo della Sofferenza
- SC Oncologia Medica 1
- Azienda Ospedaliera Istituti Ospedalieri di Cremona
- Ospedale S. Chiara - Azienda Ospedaliero-Universitaria Pisana
- Arcispedale Santa Maria Nuova
- Regina Elena National Cancer Institute
- Ospedale Borgo Roma
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Nab-FOLFIRI
Nab-FOLFOX
In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity. Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence.
In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity. Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence